BOSENTAN - AN OVERVIEW

In WHO Functional Class II patients, take into consideration regardless of whether the advantages of bosentan are adequate to offset the potential risk of hepatotoxicity, which can preclude long term use as their illness progresses.Bosentan and Ro 48-5033 are already demonstrated to be substrates from the human organic anion transporting polypeptid